A detailed history of Advisor Net Financial, Inc transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Advisor Net Financial, Inc holds 36 shares of HALO stock, worth $1,935. This represents 0.0% of its overall portfolio holdings.

Number of Shares
36
Previous 36 -0.0%
Holding current value
$1,935
Previous $1,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 12, 2024

BUY
$33.68 - $41.95 $505 - $629
15 Added 71.43%
36 $1,000
Q4 2023

Jan 19, 2024

BUY
$33.32 - $42.1 $66 - $84
2 Added 10.53%
21 $0
Q3 2023

Oct 12, 2023

BUY
$36.46 - $44.03 $109 - $132
3 Added 18.75%
19 $0
Q2 2023

Jul 14, 2023

BUY
$30.28 - $38.74 $484 - $619
16 New
16 $0
Q4 2022

Jan 13, 2023

BUY
$40.06 - $59.44 $761 - $1,129
19 New
19 $0

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $7.49B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Advisor Net Financial, Inc Portfolio

Follow Advisor Net Financial, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Net Financial, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Advisor Net Financial, Inc with notifications on news.